(Adds details on the deal in paragraphs 2-4)
Sept 18 (Reuters) - Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant , for up to $1.2 billion.
Organon will make an upfront payment of $175 million, as well as milestone payments of $75 million and up to $950 million upon achievement of certain commercial milestones.
Dermavant's VTAMA psoriasis cream was approved by the U.S. Food and Drug Administration in May 2022. Psoriasis is a common chronic inflammatory skin disease.
The company expects to close the transaction in the fourth quarter of this year.
(Reporting by Sneha S K; Editing by Vijay Kishore)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.